

1 **von Willebrand factor-related values can predict bleeding events in patients with left**
2 **ventricular assist devices**

3

4 Ryuichi Taketomi^{1,2}, MD, Ko Sakatsume^{1,2}, PhD, Shintaro Katahira¹, PhD, Kota Goto², MD,

5 Misako Suzuki², MD, Zuo Yunan¹, PhD, Konosuke Sasaki^{1,3}, PhD, Midori Miyatake¹, PhD,

6 Katsuhiko Hosoyama¹, PhD, Koki Ito¹, PhD, Yusuke Suzuki¹, PhD, Goro Takahashi¹, PhD,

7 Kiichiro Kumagai¹, PhD, Hisanori Horiuchi², PhD, and Yoshikatsu Saiki¹, PhD.

8 1. Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai,

9 Japan

10 2. Department of Molecular and Cellular Biology, Institute of Development, Aging, and Cancer,

11 Tohoku University, Sendai, Japan

12 3. Oncology Nursing, Health Sciences, Tohoku University Graduate School of Medicine, Sendai,

13 Japan

14

15 **Short title: VWF predicts bleeding in LVAD patients**

16

17 Corresponding authors:

18 1. Yoshikatsu Saiki, MD, PhD. Division of Cardiovascular Surgery, Tohoku University Graduate

19 School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai, 980-8574 Japan. Tel: +81-22-7177222; fax:

20 +81-22-7177227; e-mail: yoshisaiki@med.tohoku.ac.jp.

21 2. Hisanori Horiuchi, MD, PhD. Department of Molecular and Cellular Biology, Institute of

22 Development, Aging, and Cancer, Tohoku University, Sendai, Japan, 4-1 Seiryomachi, Aoba-ku,

23 Sendai, 980-8575 Japan. Tel: +81-22-7178463; fax: +81-22-7178463; e-mail:

24 hisanorihoriuchi@gmail.com

25

26 Total word count of the manuscript (including Title Page, Abstract, Text, References, Tables and

27 Figures Legends) : 5998 words

28

29 **Abstract**

30 **Background:** Recent advances in left ventricular assist device (LVAD) therapy have significantly
31 contributed to the improved management of severe heart failure. The unignorable risk of bleeding
32 events associated with the device therapy, however, remains to be addressed. Predictive factors for
33 bleeding events are not fully defined.

34 **Methods:** Patients implanted with various types of LVADs were assessed for von Willebrand factor
35 (VWF)-related values and platelet proteins from 2011 to 2023 at Tohoku University Hospital. We
36 evaluated the relationship between these parameters and bleeding events at remote periods after
37 LVAD implantation.

38 **Results:** The VWF large multimer index (VWF-LMI), the ratio of VWF ristocetin cofactor activity
39 to VWF antigen level (VWF:RCo/VWF:Ag), and maximal ristocetin (1.2 µg/mL) induced platelet
40 aggregation (RIPA) rates decreased in a pump speed- and device type-dependent manner. Major
41 bleeding events, defined according to the Interagency Registry for Mechanically Assisted
42 Circulatory Support criteria, occurred in 28.8% (19/66) of the patients. Kaplan–Meier methods,
43 log-rank tests, and Cox regression analyses revealed that VWF-LMI <42.3 (p=0.0002),
44 VWF:RCo/VWF:Ag <0.52 (p=0.0239), and maximal RIPA rate <79.2 (p=0.0012) predicted bleeding
45 events with hazard ratios of 6.96, 2.89, and 13.4, respectively. The platelets of the patients with
46 LVAD support exhibited significantly reduced expression levels of glycoprotein α (GPVI;

47 p=0.0334) and glycoprotein α b (GPIb; p=0.0061) compared with healthy subjects. Nevertheless,
48 patients with bleeding events did not exhibit reduced GPVI (p=0.5267) or GPIb (p=0.6674) levels
49 compared to those without bleeding events.

50 **Conclusions:** VWF-related values, including VWF-LMI, VWF:RCo/VWF:Ag, and maximal RIPA
51 rate, but not reduced platelet proteins, predicted bleeding events in patients with LVADs.

52

53 **Registration:** URL: <https://www.umin.ac.jp/ctr/>; Unique identifier: UMIN000027761

54

55 **Keywords:** left ventricular assist device, bleeding event, von Willebrand factor, platelet protein,
56 ristocetin-induced platelet aggregation

57

58 **Clinical Perspective**

59 **What Is New ?**

60 • Comprehensive measurements of von Willebrand factor-related values, platelet proteins, and
61 ristocetin-induced platelet aggregation rates were obtained in patients with left ventricular assist
62 device support to evaluate their association with bleeding events.

63 • The von Willebrand factor large multimer index, ratio of von Willebrand factor ristocetin cofactor
64 activity to von Willebrand factor antigen levels, and maximal ristocetin-induced platelet aggregation
65 rate predicted bleeding events in patients implanted with a left ventricular assist device.

66 **What Are the Clinical Implications ?**

67 • Predictors of bleeding events in patients with left ventricular assist device support were identified
68 in this study. Understanding how von Willebrand factor-related values are associated with bleeding
69 events will facilitate the management of potential bleeding events.

70 • The ratio of von Willebrand factor ristocetin cofactor activity to von Willebrand factor antigen
71 levels is a predictor of bleeding events that can be measured and evaluated relatively easily in many
72 centers without special techniques or equipment, in contrast to analysis of the von Willebrand factor
73 large multimer index.

74 **Introduction**

75 Left ventricular assist devices (LVADs) have made tremendous contributions to the
76 treatment of severe heart failure; however, they are associated with complications such as infection,
77 thrombosis, stroke, and bleeding events, which is most commonly gastrointestinal tract bleeding¹⁻³.

78 LVAD-associated bleeding is thought to be caused by unphysiologically high shear stress
79 inside the pump, which causes degradation of high-molecular-weight (large) von Willebrand factor
80 (VWF) multimers having a critical role in hemostasis, leading to a hemostatic disorder known as
81 acquired von Willebrand syndrome (AVWS)^{4,5}. Platelet function is also reportedly impaired in
82 patients with LVADs due to the shedding of glycoprotein α (GPVI) and glycoprotein β (GPIb),
83 platelet proteins with important roles in hemostasis⁶⁻⁹. Several months after LVAD implantation,
84 fragile and abnormal vessels called angiodysplasia lesions develop in the gastrointestinal tract just
85 underneath the epithelial cells¹⁰⁻¹². Thus, gastrointestinal bleeding at remote periods after
86 implantation typically derives from angiodysplasia lesions under impaired hemostatic conditions due
87 to dysfunction of VWFs and/or platelets.

88 Recently developed LVADs with a lower shear stress in the pump seem to be related with
89 fewer LVAD-associated gastrointestinal bleeding events^{13,14}. Nevertheless, bleeding events remain a
90 common complication in patients with LVADs, accounting for nearly 20.0% of hospital readmissions
91¹⁵. Patients with LVADs exhibit a remarkably severe loss of VWF large multimers compared to

92 patients with severe aortic stenosis based on the VWF large multimer index (VWF-LMI), a
93 quantitative score we proposed^{5,16-24} and have widely used²⁵⁻²⁷ to evaluate VWF large multimers in
94 VWF multimer analysis. In the present study, we demonstrated that patients with a bleeding event
95 had significantly lower VWF-LMI values compared to patients without a bleeding event¹⁸.

96 The strength of the contribution of VWF impairment and/or platelet dysfunction to
97 bleeding events in patients with LVADs remains unclear. More importantly, no common measures to
98 predict LVAD-associated bleeding events have been developed. To address these issues, we
99 evaluated the association between bleeding events in patients with LVADs and their VWF-related
100 values, including VWF-LMI and platelet protein levels, in patients who underwent LVAD
101 implantation at Tohoku University Hospital.

102

103 **Methods**

104 **Participants**

105 Patients who underwent LVAD implantation at Tohoku University Hospital between July
106 2011 and June 2023, were analyzed. Hematologic analyses were performed when patients were
107 stable. The association between the results of the hematologic analyses and “major bleeding” events
108 as defined in the IMACS criteria, including suspected internal or external bleeding resulting in death,
109 re-operation, hospitalization, and/or transfusion of red blood cells²⁸, excluding perioperative events,

110 was evaluated.

111 We previously reported an analysis of 41 patients who underwent LVAD implantation and
112 were followed at Tohoku University¹⁸. Of those 41 patients, 2 patients were excluded from the
113 analysis as the analyzed blood samples were not obtained under a stable condition (Supplementary
114 figure 1) and 39 patients were analyzed here. Following that report, another 33 patients underwent
115 LVAD implantation at Tohoku University Hospital by June 2023. Excluding 6 patients who declined
116 to participate, transferred to another hospital, or died from postoperative complications, 27 patients
117 were enrolled in the present study. Thus, a total 66 patients with LVADs were analyzed here.

118 Platelet proteins and ristocetin-induced platelet aggregation (RIPA) levels were analyzed
119 in 30 of the 66 patients implanted with LVADs by September 2022, and in 10 enrolled healthy
120 subjects who were not currently taking any medications.

121

122 **Laboratory data**

123 Blood samples, collected in sodium citrate at least 1 month after LVAD implantation when
124 patients were stable, were centrifuged at $150 \times g$ for 10 min at room temperature to isolate
125 platelet-rich plasma (PRP). Centrifugation at $2,000 \times g$ for 5 min at room temperature was
126 performed to obtain platelet poor plasma (PPP). Within 2 h after obtaining the PRP and PPP samples,
127 1.2 mg/mL ristocetin was added and RIPA was measured using an automated blood coagulation

128 analyzer (CN6000, Sysmex Corp, Kobe, Japan) according to the manufacturer's instructions. The
129 PRP was also utilized for platelet isolation through gel filtration chromatography ²⁹. Isolated
130 platelets were suspended in Laemmli's sodium dodecyl sulfate-containing buffer with
131 2-mercaptoethanol and stored at -80°C until use. In parallel, the collected blood samples were
132 centrifuged at 1,200 × g for 10 min at 4°C to obtain plasma. The obtained plasma was stored at
133 -80°C until use.

134 The VWF ristocetin cofactor activity (VWF:RCo) and VWF antigen levels (VWF:Ag) in
135 the plasma samples from each of the patients were measured with the CN6000 (Sysmex Corp)
136 according to the manufacturer's instructions.

137

138 **von Willebrand factor large multimer index**

139 VWF-LMI was analyzed using a 1.0% agarose gel to which equal amounts of VWF:Ag
140 were applied under non-reducing conditions followed by Western blotting using FITC-labelled
141 polyclonal rabbit anti-human VWF antibody (DAKO, Glostrup, Denmark) as the primary antibody.
142 The Western blotting analysis probing VWF was visualized by ImmunoStarVR Zeta
143 chemiluminescence (Wako, Osaka, Japan) and evaluated using Amersham ImageQuant800 (Cytiva,
144 Marlborough, MA, USA) and ImageJ. Bands above the 10th lowest band were classified as large
145 multimers. Based on densitometric analysis, the VWF-LMI was calculated as the percentage of a

146 patient's VWF large multimer ratio to that of the control (Siemens Standard plasma) analyzed in the
147 lane adjacent to the patient's plasma, as described previously^{5,16-23,25-27}.

148

149 **Western blotting for platelet proteins evaluation**

150 Proteins in the platelet lysate of each patient and control subject, which contained an equal
151 amount of tubulin, were separated by sodium-dodecyl sulphate polyacrylamide-gel electrophoresis
152 using 12.5% e-PAGEL gel (ATTO, Tokyo, Japan). They were then transferred to a nitrocellulose
153 membrane, Protran BA85 (Cytiva), and Western blotting was performed. The primary antibodies
154 used in this study are listed in Supplementary figure 2. Secondary antibodies were mouse
155 anti-human IgG (Jackson ImmunoResearch, West Grove, PA, USA), rabbit anti-human IgG (Jackson
156 ImmunoResearch) or sheep anti-human IgG (R&D Systems, MN, USA). It was finally visualized by
157 ImmunoStar Zeta chemiluminescence (Wako) and quantified using Amersham ImageQuant800
158 (Cytiva) and ImageJ, using the amount of a specific healthy person as 100%.

159

160 **Statistical analyses**

161 All statistical analyses were performed using GraphPad Prism version 10 (GraphPad
162 Software, San Diego, CA, USA). Continuous variables are expressed as mean \pm standard
163 deviation. Categorical variables are presented as frequencies and percentages, and inter-group

164 comparisons of categorical variables were analyzed using Fisher's exact test or the χ^2 test.
165 Intergroup comparisons of continuous variables were performed using Student's t-test or the Mann
166 Whitney test if normally distributed. Bleeding event-free survivals were analyzed using the
167 Kaplan–Meier method, log-rank test, and Cox regression analysis. Differences were considered
168 significant when the P-value was less than 0.050.

169

170 **Ethics**

171 This study was performed in accordance with the Declaration of Helsinki. The study
172 protocol was approved by the Institutional Ethics Committee in Tohoku University (Certification
173 number; 2017-1-386 and 2020-1-935). The study protocol was also registered in the University
174 Hospital Medical Information Network (UMIN) (UMIN number; UMIN000027761). Written
175 informed consent was obtained from each participant.

176

177 **Results**

178 **Participant characteristics**

179 In this study, we analyzed 66 patients with LVADs, as described above (Supplementary
180 figure 1). Age, sex, and blood type did not differ significantly between healthy subjects and patients
181 (Table 1). Patients underwent implantation of various types of LVADs; a centrifugal-type LVAD,

182 including the EVAHEART (Sun Medical Technology Research Corp., Nagano, Japan; n=9),
183 HeartMate3 (Abbott, Chicago, IL, USA; n=12), HVAD (Medtronic, Framingham, MA, USA; n=4),
184 DuraHeart (Terumo, Tokyo, Japan; n=4); or an axial-type LVAD, including the Jarvik2000 (Jarvik
185 Heart Inc, New York, NY, USA; n=10) and HeartMate \square (Abbott, Chicago, IL, USA; n=27;Table 1).

186

187 **Evaluation of VWF-LMI**

188 VWF multimer analysis of the patients' plasmas was performed by Western blotting under
189 non-reducing conditions (Figure 1A). VWF large multimers were evaluated with the VWF-LMI as
190 described in the Methods. The mean VWF-LMI of the patients was $47.9 \pm 25.4\%$. We have proposed
191 that VWF-LMI<80.0% reasonably indicates loss of VWF large multimers²⁴, and 57 of 66 patients
192 (86.3%) had VWF-LMI<80.0%. Patients with a centrifugal-type LVAD had a higher VWF-LMI than
193 patients with an axial-type LVAD ($p<0.001$), and patients implanted with an HVAD and DuraHeart
194 had a lower VWF-LMI (Figure 1B). The low VWF-LMIs in patients implanted with an HVAD and
195 DuraHeart having a low pump speed might be due to their outlets with narrow diameters. The
196 VWF-LMI decreased in a pump speed-dependent manner ($p<0.001$, $r=-0.599$; Figure 1C).

197

198 **Evaluation of VWF:RCo/VWF:Ag**

199 The ratio of VWF:RCo to VWF:Ag can be measured in plasma by an automated blood

200 coagulation analyzer. VWF:RCo/VWF:Ag <0.70 is used for the diagnosis of hereditary von
201 Willebrand disease. The mean VWF:RCo/VWF:Ag for the 66 patients with LVADs was rather low
202 (0.53±0.22), and 51 of 66 patients (77.3%) had VWF:RCo/VWF:Ag <0.70. The VWF-LMI
203 positively correlated with the VWF:RCo/VWF:Ag (p<0.001, r=0.468; Figure 2A). Nevertheless,
204 VWF:RCo/VWF:Ag did not correlate with the device type or pump speed (Figure 2B and C).

205

206 **Evaluation of RIPA**

207 Ristocetin is known to induce GPIb platelet protein binding to VWF, which causes platelet
208 aggregation. We analyzed RIPA in 30 patients with LVADs among the enrolled 66 patients as shown
209 in Supplementary figure 1. The mean maximal RIPA rates were 81.4±11.9%, and did not differ
210 significantly from those of healthy subjects, 82.0±8.3% (p=0.834). Nevertheless, VWF-LMI
211 positively correlated with the maximal RIPA rate (p<0.001, r=0.660; Figure 3A). Patients with a
212 centrifugal-type LVAD had a higher maximum RIPA rate compared to patients with an axial-type
213 LVAD (p=0.004) and these values differed significantly between the EVAHEART and Jarvik2000
214 when comparing each device individually (p=0.010; Figure 3B). Maximal RIPA rates decreased in a
215 pump-speed dependent manner (p<0.001, r=-0.664; Figure 3C).

216

217 **Bleeding events**

218 Nineteen patients developed bleeding events among the enrolled 66 patients during the
219 observation period until heart transplantation, death, or bleeding event. Patients developing a
220 bleeding event are summarized in Table 2. Of the 19 patients who developed a bleeding event, 13
221 had gastrointestinal bleeding. Cases 4, 7, 8, and 14 were admitted for evaluation of anemia despite
222 having no bleeding symptoms. All patients were kept on warfarin. Their prothrombin
223 time-international normalized ratios (PT-INRs) were within or below the target range (EVAHEART:
224 2.5-3.5, other devices: 2.0-3.0) except 1 patient whose PT-INR exceeded only slightly the target
225 range at 3.13. Comparison of patients with bleeding events (Bleeding (+)) and those without
226 bleeding events (Bleeding (-)) by univariate analysis revealed significant differences in device type,
227 days on LVAD, VWF-LMI, VWF:RCo/VWF:Ag, lactate dehydrogenase, and platelet counts (Table
228 3). Following multivariate analysis with these factors, however, only VWF-LMI remained
229 statistically significant ($p=0.045$).

230

231 **Kaplan-Meier curves for bleeding events**

232 The receiver operating characteristics (ROC) analysis determined a cutoff value of 42.3%
233 for VWF-LMI in relation to bleeding events (sensitivity 0.68, specificity 0.84). Using this cutoff
234 value, patients were divided into 2 groups and the Kaplan-Meier curve revealed a significant
235 increase in bleeding events in patients with VWF-LMI <42.3% compared to patients with VWF-LMI

236 $\geq 42.3\%$ ($p < 0.001$, hazard ratio [HR] 6.96 [95% confidence interval [CI] 2.81-17.2]; Figure 4A).

237 The ROC analysis determined a cutoff value of 0.52 for VWF:RCo/VWF:Ag with respect
238 to bleeding events (sensitivity 0.68, specificity 0.68). Using this cutoff value, patients were divided
239 into 2 groups and the Kaplan-Meier curve revealed a significant increase in bleeding events in
240 patients with VWF:RCo/VWF:Ag < 0.52 compared to patients with VWF:RCo/VWF:Ag ≥ 0.52
241 ($p = 0.024$, HR 2.89 [95%CI 1.17-7.17]; Figure 4B)

242 Six of the 30 patients (20.0%) analyzed for RIPA developed bleeding events. The ROC
243 analysis determined a cutoff value of 79.2% for maximal RIPA rate with respect to bleeding events
244 (sensitivity 0.79, specificity 0.83). Using this cutoff value, patients were divided into 2 groups and
245 the Kaplan-Meier curve revealed a significant increase in bleeding events in the patients with a
246 maximal RIPA rate $< 79.2\%$ compared to patients with a maximal RIPA rate $\geq 79.2\%$ ($p = 0.001$, HR
247 13.4 [95%CI 2.22-81.17]; Figure 4C)

248

249 **Evaluation of platelet proteins**

250 We first confirmed the high specificity of each primary antibody to ensure its adequacy for
251 use in the present study (Figure 5A). With the antibodies, platelets isolated from 30 patients were
252 analyzed by Western blotting by calibrating the PRP volumes based on the amount of tubulin in a
253 control healthy subject. Each result was expressed as a percentage of the control healthy subject's

254 expression level. Among 11 platelet proteins, including PAR-1, GPIIIa, P2Y12, and P-selectin, lower
255 expression levels of GPIb (89.3 ± 6.3 vs 77.4 ± 18.2 , $p=0.006$) and GPVI (108.8 ± 9.0 vs 81.3 ± 33.6 ,
256 $p=0.033$) were observed in patients with LVADs ($n=30$) compared to healthy subjects ($n=10$).
257 Expression levels of PAR-1 ($p=0.210$), TXA2R ($p=0.221$), GPIIIa ($p=0.842$), FcR γ ($p=0.678$), P2Y1
258 ($p=0.072$), P2Y12 ($p=0.188$), 5-HTR2 ($p=0.286$), PGI2R ($p=0.770$), and P-selectin ($p=0.358$) did not
259 differ significantly between patients and controls (Figure 5B). The levels of GPIb or GPVI were not
260 associated with the device type or pump speed. Further, the levels of GPIb and GPVI were not
261 different between Bleeding (+) and Bleeding (-) ($p=0.667$ and $p=0.890$, respectively)
262 (Supplementary figure 3).

263

264 **Discussion**

265 The findings of the present study demonstrated that 19 (28.8%) of the 66 patients with
266 LVADs developed bleeding events during a mean follow-up of 1386.7 ± 667.0 days after LVAD
267 implantation. Patients with bleeding events ($n=19$) had lower VWF-LMI, VWF:RCo/VWF:Ag, and
268 maximal RIPA rate than those without bleeding events. The Kaplan-Meier curve showed that
269 VWF-LMI $<42.3\%$ ($p<0.001$), VWF:RCo/VWF:Ag <0.52 ($p=0.024$), and maximal RIPA rate
270 $<79.2\%$ ($p=0.001$) predicted bleeding events with HRs of 6.96, 2.89, and 13.42, respectively. Thus,
271 we have first found predictive factors for bleeding events in patients with LVAD that are

272 VWF-related values including VWF-LMI, VWF:RCo/VWF:Ag and maximal RIPA rates.

273 VWF:RCo/VWF:Ag <0.70 is used to diagnose von Willebrand disease type 2A³⁰ and can

274 be measured by an automated hemostatic analyzer in ordinary hospitals. Thus, measuring this ratio is

275 much more feasible than measuring VWF-LMI that requires a special Western blotting technique for

276 analyzing huge VWF multimers of ~20,000,000 daltons, and RIPA that requires freshly collected

277 patient's platelets and a light-transmission platelet aggregometer. Furthermore, we have recently

278 reported that VWF:RCo/VWF:Ag <0.70 predicts a loss of VWF large multimers, defined as

279 VWF-LMI <80.0%, with high specificity, but low sensitivity in patients with severe aortic stenosis

280 (AS)²⁴. This is probably due to the relatively low degree of loss of VWF large multimers in AS

281 patients having VWF-LMI of 70.0%-80.0% and many AS patients exhibited VWF:RCo/VWF:Ag

282 around 0.70²⁴. VWF:RCo/VWF:Ag in many AS patients were overlapped with those in healthy

283 subjects. Therefore, use of VWF:RCo/VWF:Ag could be limited for the diagnosis of AVWS in AS

284 patients. In contrast, VWF-LMIs in patients with LVADs in the present study were 20.0%-80.0%

285 ($47.9 \pm 25.4\%$), which were much lower compared to those in patients with severe AS. Accordingly,

286 the positive predictive value of VWF:RCo/VWF:Ag < 0.70 for VWF-LMI < 80.0% is very high with

287 45/51 (88.2%). Thus, VWF:RCo/VWF:Ag <0.70 could be a useful indicator to monitor the loss of

288 VWF large multimers in patients with LVADs.

289 The VWF:RCo/VWF:Ag correlated with VWF-LMI. The majority (51/66; 77.3%) of

290 patients had a VWF:RCo/VWF:Ag <0.70. Importantly, VWF:RCo/VWF:Ag <0.52 predicted
291 bleeding events (p=0.024) with an HR of 2.89 as described above. Thus, VWF:RCo/VWF:Ag may
292 be a useful predictor in centers where VWF-LMI and RIPA are difficult to measure. Since
293 VWF-LMI, which predicted bleeding events with an HR 6.96, is a better predictor than
294 VWF:RCo/VWF:Ag, VWF-LMI is recommended in centers where it can be measured.

295 Maximal RIPA rates also predicted bleeding events, as did VWF-LMI and
296 VWF:RCo/VWF:Ag. However, the reduction in maximal RIPA rates was smaller, with a mean
297 maximal RIPA rates of 81.4% and a cut-off value of 79.2% for bleeding events in 30 patients with
298 LVAD. This may be due to high ristocetin concentrations used for the purpose of differentiating von
299 Willebrand disease.

300 We recently demonstrated individual variability in VWF fragility in response to shear
301 stress ex vivo²¹. In this study, VWF-LMI varied from 40.0%-90.0%, even in patients with the
302 HeartMate3, which is currently the most frequently implanted LVAD in the world and is associated
303 with fewer bleeding events, indicating individual differences in VWF vulnerability to shear stress¹⁴.
304 It is therefore important to measure VWF-related factors, since even in patients with LVADs
305 producing low shear stress, there are patients with a degraded VWF large multimer.

306 Regarding the association between bleeding events and the expression levels of platelet
307 proteins, Mondal et al reported that patients with LVADs (n=51) had lower expression levels of GPIIb

308 and GPVI than healthy subjects, and that patients with bleeding events had lower GPIb and GPVI
309 expression levels than those without bleeding events⁹. It is unclear why decreased GPIb or GPVI
310 was not associated with bleeding events in our study. We consider following reasons; (1) Mondal et
311 al analyzed patients treated with HeartMateII, Jarvik2000, and HVAD⁹, which degraded VWF
312 multimers more severely shown in this study. They did not, however, analyze VWF. It is highly
313 likely that the patients with bleeding events in their report had reduced VWF large multimers as well
314 as reduced levels of platelet proteins. (2) Although the definitions of bleedings were based on the
315 INTERMACS criteria in both studies, our study excluded perioperative events due to the greater
316 influence of the surgical technique and unstable hemodynamics in the immediate postoperative
317 period. It is possible that platelet surface protein levels are more strongly associated with
318 perioperative bleeding events than AVWS.

319 In conclusion, we demonstrated that VWF-related values including VWF-LMI,
320 VWF:RCo/VWF:Ag, and maximal RIPA rates, but not expression levels of the platelet proteins
321 GPIb or GPVI, could predict bleeding events in patients with LVADs.

322

323 **Limitations**

324 A limitation of this study is that it was a retrospective single-center study analyzing a
325 relatively small number of patients. Especially for platelet protein levels and RIPA, only 30 cases

326 were analyzed.

327

328 **Conclusions**

329 VWF-LMI, VWF:RCo/VWF:Ag, and maximal RIPA rates can be predictive factors of

330 bleeding events in patients with LVADs.

331

332 **Sources of Funding**

333 This research was supported by Japan Agency for Medical Research and Development grant

334 22ek0109475h0003 and Japan Society for the Promotion of Science KAKENHI grant 20H03760.

335

336 **Disclosures**

337 A part of this study was performed in collaboration with Sysmex Corporation.

338

339

340

341

342

343

344

345

346 **References**

347 1. McNamara N, Narroway H, Williams M, Brookes J, Farag J, Cistulli D, Bannon P,

348 Marasco S, Potapov E, Loforte A. Contemporary outcomes of continuous-flow left ventricular assist

349 devices-a systematic review. *Ann Cardiothorac Surg.* 2021;10:186-208. doi:

350 10.21037/acs-2021-cfmcs-35

351 2. Michelis KC, Zhong L, Peltz M, Pandey A, Tang WHW, Rohatgi A, Young JB, Drazner

352 MH, Grodin JL. Dynamic Forecasts of Survival for Patients Living With Destination Left

353 Ventricular Assist Devices: Insights From INTERMACS. *J Am Heart Assoc.* 2020;9:e016203. doi:

354 10.1161/JAHA.119.016203

355 3. Llerena-Velastegui J, Santafe-Abril G, Villacis-Lopez C, Hurtado-Alzate C,

356 Placencia-Silva M, Santander-Aldean M, Trujillo-Delgado M, Freire-Ona X, Santander-Fuentes C,

357 Velasquez-Campos J. Efficacy and Complication Profiles of Left Ventricular Assist Devices in Adult

358 Heart Failure Management: A Systematic Review and Meta-analysis. *Curr Probl Cardiol.*

359 2023;102118. doi: 10.1016/j.cpcardiol.2023.102118

360 4. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, Fujimura Y. Platelets

361 treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are

362 those treated with aspirin under high shear stress. *Pathophysiol Haemost Thromb*. 2005;34:35-40.

363 doi: 10.1159/000088546

364 5. Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von Willebrand

365 Syndrome Associated with Cardiovascular Diseases. *J Atheroscler Thromb*. 2019;26:303-314. doi:

366 10.5551/jat.RV17031

367 6. Chen Z, Mondal NK, Ding J, Gao J, Griffith BP, Wu ZJ. Shear-induced platelet receptor

368 shedding by non-physiological high shear stress with short exposure time: glycoprotein Ibalpha and

369 glycoprotein VI. *Thromb Res*. 2015;135:692-698. doi: 10.1016/j.thromres.2015.01.030

370 7. Chen Z, Zhang J, Li T, Tran D, Griffith BP, Wu ZJ. The impact of shear stress on

371 device-induced platelet hemostatic dysfunction relevant to thrombosis and bleeding in mechanically

372 assisted circulation. *Artif Organs*. 2020;44:E201-E213. doi: 10.1111/aor.13609

373 8. Lukito P, Wong A, Jing J, Arthur JF, Marasco SF, Murphy DA, Bergin PJ, Shaw JA,

374 Collecutt M, Andrews RK, et al. Mechanical circulatory support is associated with loss of platelet

375 receptors glycoprotein Ibalpha and glycoprotein VI. *J Thromb Haemost*. 2016;14:2253-2260. doi:

376 10.1111/jth.13497

377 9. Mondal NK, Chen Z, Trivedi JR, Sorensen EN, Pham SM, Slaughter MS, Griffith BP, Wu

378 ZJ. Association of Oxidative Stress and Platelet Receptor Glycoprotein GPIbalpha and GPVI

379 Shedding During Nonsurgical Bleeding in Heart Failure Patients With Continuous-Flow Left

380 Ventricular Assist Device Support. *ASAIO J.* 2018;64:462-471. doi:
381 10.1097/MAT.0000000000000680

382 10. Akiyama M, Sakatsume K, Sasaki K, Kawatsu S, Yoshioka I, Takahashi G, Kumagai K,
383 Adachi O, Saiki Y. The incidence, risk factors, and outcomes of gastrointestinal bleeding in patients
384 with a left ventricular assist device: a Japanese single-center cohort study. *J Artif Organs.*
385 2020;23:27-35. doi: 10.1007/s10047-019-01138-y

386 11. Bartoli CR, Zhang DM, Hennessy-Strahs S, Kang J, Restle DJ, Bermudez C, Atluri P,
387 Acker MA. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von
388 Willebrand Factor Degradation Alters Angiogenesis. *Circ Heart Fail.* 2018;11:e004638. doi:
389 10.1161/CIRCHEARTFAILURE.117.004638

390 12. Kang J, Hennessy-Strahs S, Kwiatkowski P, Bermudez CA, Acker MA, Atluri P,
391 McConnell PI, Bartoli CR. Continuous-Flow LVAD Support Causes a Distinct Form of Intestinal
392 Angiodysplasia. *Circ Res.* 2017;121:963-969. doi: 10.1161/CIRCRESAHA.117.310848

393 13. Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, Patel CB, Ewald
394 GA, Tatrooles AJ, Silvestry SC, et al. Hemocompatibility-Related Outcomes in the MOMENTUM 3
395 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in
396 Advanced Heart Failure. *Circulation.* 2017;135:2003-2012. doi:
397 10.1161/CIRCULATIONAHA.117.028303

- 398 14. Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, Naka Y,
399 Horstmanshof D, Chuang J, Wang A, et al. Five-Year Outcomes in Patients With Fully Magnetically
400 Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.
401 JAMA. 2022;328:1233-1242. doi: 10.1001/jama.2022.16197
- 402 15. Cai J, Xia W, Greenberg P, Okwuosa I, Setoguchi S, Akhabue E. Relation of
403 Sociodemographic Factors With Primary Cause of Hospitalization Among Patients With Left
404 Ventricular Assist Devices (from the National Inpatient Sample 2012 to 2017). Am J Cardiol.
405 2022;180:81-90. doi: 10.1016/j.amjcard.2022.06.047
- 406 16. Tamura T, Horiuchi H, Imai M, Tada T, Shiomi H, Kuroda M, Nishimura S, Takahashi Y,
407 Yoshikawa Y, Tsujimura A, et al. Unexpectedly High Prevalence of Acquired von Willebrand
408 Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index.
409 J Atheroscler Thromb. 2015;22:1115-1123. doi: 10.5551/jat.30809
- 410 17. Sakatsume K, Akiyama M, Saito K, Kawamoto S, Horiuchi H, Saiki Y. Intractable
411 bleeding tendency due to acquired von Willebrand syndrome after Jarvik 2000 implant. J Artif
412 Organs. 2016;19:289-292. doi: 10.1007/s10047-016-0896-7
- 413 18. Sakatsume K, Saito K, Akiyama M, Sasaki K, Kawatsu S, Takahashi G, Adachi O,
414 Kawamoto S, Horiuchi H, Saiki Y. Association between the severity of acquired von Willebrand
415 syndrome and gastrointestinal bleeding after continuous-flow left ventricular assist device

- 416 implantation. *Eur J Cardiothorac Surg*. 2018;54:841-846. doi: 10.1093/ejcts/ezy172
- 417 19. Tamura T, Horiuchi H, Obayashi Y, Fuki M, Imanaka M, Kuroda M, Nishimura S, Amano
418 M, Sakamoto J, Tamaki Y, et al. Acquired von Willebrand syndrome in patients treated with
419 veno-arterial extracorporeal membrane oxygenation. *Cardiovasc Interv Ther*. 2019;34:358-363. doi:
420 10.1007/s12928-019-00568-y
- 421 20. Shiraishi Y, Tachizaki Y, Inoue Y, Hayakawa M, Yamada A, Kayashima M, Matsumoto M,
422 Horiuchi H, Yambe T. Hemolysis and von Willebrand factor degradation in mechanical shuttle shear
423 flow tester. *J Artif Organs*. 2021;24:111-119. doi: 10.1007/s10047-020-01219-3
- 424 21. Sakatsume K, Akiyama M, Sakota D, Hijikata W, Horiuchi H, Maruyama O, Saiki Y.
425 Individual Variability in von Willebrand Factor Fragility in Response to Shear Stress: A Possible
426 Clue for Predicting Bleeding Risk. *Asaio j*. 2022;68:1128-1134. doi:
427 10.1097/mat.0000000000001623
- 428 22. Oishi H, Okada Y, Suzuki Y, Hirama T, Ejima Y, Fujimaki SI, Sugawara S, Okubo N,
429 Horiuchi H. Impact of intraoperative use of venovenous extracorporeal membrane oxygenation on
430 the status of von Willebrand factor large multimers during single lung transplantation. *J Thorac Dis*.
431 2023;15:4262-4272. doi: 10.21037/jtd-23-275
- 432 23. Yashige M, Inoue K, Zen K, Kobayashi R, Nakamura S, Fujimoto T, Takamatsu K, Sugino
433 S, Yamano M, Yamano T, et al. Gastrointestinal Angiodysplasia before and after Treatment of Severe

- 434 Aortic Stenosis. *N Engl J Med*. 2023;389:1530-1532. doi: 10.1056/NEJMc2306027
- 435 24. Okubo N, Sugawara S, Fujiwara T, Sakatsume K, Doman T, Yamashita M, Goto K,
436 Tateishi M, Suzuki M, Shirakawa R, et al. VWF:RCo/VWF:Ag for diagnosis of acquired von
437 Willebrand syndrome caused by aortic stenosis. *Research and Practice in Thrombosis and*
438 *Haemostasis*. 2023. doi: 10.1016/j.rpth.2023.102284
- 439 25. de Jong A, Dirven RJ, Oud JA, Tio D, van Vlijmen BJM, Eikenboom J. Correction of a
440 dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated
441 allele-specific inhibition of mutant von Willebrand factor. *J Thromb Haemost*. 2018;16:1357-1368.
442 doi: 10.1111/jth.14140
- 443 26. Boender J, Atiq F, Cnossen MH, van der Bom JG, Fijnvandraat K, de Meris J, de Maat
444 MPM, van Galen KPM, Laros-van Gorkom BAP, Meijer K, et al. Von Willebrand Factor Multimer
445 Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von
446 Willebrand Disease. *Hemasphere*. 2021;5:e542. doi: 10.1097/HS9.0000000000000542
- 447 27. Nakamura M, Imamura T, Ueno H, Kinugawa K. Impact of the Severity of Acquired von
448 Willebrand Syndrome on the Short-Term Prognosis in Patients with Temporary Mechanical
449 Circulatory Support. *Medicina (Kaunas)*. 2022;58. doi: 10.3390/medicina58020238
- 450 28. Pienta MJ, Wu X, Cascino TM, Brescia AA, Abou El Ela A, Zhang M, McCullough JS,
451 Shore S, Aaronson KD, Thompson MP, et al. Advancing Quality Metrics for Durable Left

452 Ventricular Assist Device Implant: Analysis of the Society of Thoracic Surgeons Intermacs Database.

453 Ann Thorac Surg. 2022;113:1544-1551. doi: 10.1016/j.athoracsur.2022.01.031

454 29. Yaoita N, Shirakawa R, Fukumoto Y, Sugimura K, Miyata S, Miura Y, Nochioka K, Miura

455 M, Tatebe S, Aoki T, et al. Platelets are highly activated in patients of chronic thromboembolic

456 pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2014;34:2486-2494. doi:

457 10.1161/ATVBAHA.114.304404

458 30. James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S,

459 Jacobs-Pratt V, Konkle B, McLintock C, et al. ASH ISTH NHF WFH 2021 guidelines on the

460 diagnosis of von Willebrand disease. Blood Adv. 2021;5:280-300. doi:

461 10.1182/bloodadvances.2020003265

462

463

464

465

466

467

468

469

470

471

472

473

474

475 **Table 1 Characteristics of participants in this study**

476

	Healthy subjects (n=10)	Patients with LVADs (n=66)	p value
Age (years)	38.7±12.5	46.1±13.7	0.097
Male	8	54	0.891
Blood type			0.165
A	3	21	
B	2	21	
O	3	23	
AB	2	1	
Device type			
HeartMate3		12	
EVAHEART		9	
HVAD		4	
DuraHeart		4	
HeartMate□		27	
Jarvik2000		10	
Etiology			
DCM		41	
dHCM		8	
ICM		7	
Others		10	

Days on LVAD		1386.7±667.0	
State			
Ongoing		25	
Transplanted		28	
Explanted		2	
Death		11	

477

478 Data are presented as mean±standard deviation or n (%). Age was compared by Student's t-test and

479 male and blood type by Fisher's exact test. DCM, dilated cardiomyopathy; dHCM, dilated

480 hypertrophic cardiomyopathy; ICM, ischemic cardiomyopathy.

481 **Table 2 List of patients developing bleeding events**

Case	Days on LVAD	Sex	Symptoms	Bleeding site	Device type	Antiplatelet agents	Hb (g/dL)	PT-INR	Plt (10 ³ /μL)
1	17	Male	black stool	intestine	Jarvik2000	aspirin 100 mg	6.9	1.79	20.2
2	32	Male	melena	ascending colon	Jarvik2000	aspirin 100 mg	7.7	3.13	11.8
3	142	Male	black stool	intestine	HeartMate□	aspirin 100 mg	7.8	2.85	18.4
4	159	Male	no symptoms	unknown	HeartMate□	aspirin 100 mg	6.3	2.23	32.4
5	209	Male	black stool	stomach	HeartMate□	aspirin 100 mg	7.2	2.00	13.5
6	266	Male	black stool	stomach	Jarvik2000	aspirin 100 mg	7.1	1.90	14.5
7	311	Male	no symptoms	unknown	HeartMate3	aspirin 100 mg	7.2	1.96	23.8
8	609	Male	no symptoms	unknown	HVAD	clopidogrel 75 mg	8.5	1.52	14.6
9	674	Male	black stool	intestine	HeartMate□	aspirin 100 mg	8.5	2.35	25.3
10	685	Male	melena	ascending colon	Jarvik2000	aspirin 100 mg + clopidogrel 75 mg	6.6	2.27	19.1
11	791	Male	black stool	intestine	HeartMate□	aspirin 100 mg	7.7	2.65	23.0
12	833	Male	black stool	ascending colon	Jarvik2000	aspirin 100 mg + clopidogrel 75 mg	12.4	2.84	9.4
13	843	Male	melena	ascending colon	Jarvik2000	clopidogrel 75 mg	7.4	2.40	32.2
14	868	Male	no symptoms	unknown	HVAD	aspirin 100 mg	7.1	1.18	19.4
15	1064	Female	excessive menstruation	uterus	HeartMate□	aspirin 100 mg	7.3	2.81	20.8
16	1110	Male	melena	ascending colon	HeartMate□	aspirin 100 mg	6.1	2.73	27.1

17	1123	Male	black stool	intestine	HeartMate □	aspirin 100 mg	9.1	2.29	20.9
18	1627	Female	excessive menstruation	ovary	Jarvik2000	clopidogrel 50 mg	6.5	1.77	14.7
19	2470	Female	melena	intestine	Jarvik2000	aspirin 100mg	5.4	1.43	13.1

482

483 Bleeding events defined by the Interagency Registry for Mechanically Assisted Circulatory Support criteria including suspected internal or external

484 bleeding, resulting in death, re-operation, hospitalization, and/or transfusion of red blood cells²⁸, excluding perioperative events²⁸. Hb, hemoglobin; LVAD,

485 left ventricular assist device; PT-INR, prothrombin time-international normalized ratio; Plt, platelet count.

486

Table 3 Comparison of characteristics and laboratory data between patients with bleeding events (Bleeding (+)) and patients without bleeding events (Bleeding (-))

	Bleeding (+) (n=19)	Bleeding (-) (n=47)	p value
Age (years)	49.3±13.6	44.8±13.7	0.282
Male	16	38	0.746
Blood type			0.903
A	5	16	
B	7	14	
O	7	16	
AB	0	1	
Device type			<0.001
HeartMate3	1	11	
EVAHEART	0	9	
HVAD	2	2	
DuraHeart	0	4	
HeartMate \square	8	19	
Jarvik2000	8	2	
Etiology			0.558
DCM	11	30	
dHCM	4	4	
ICM	2	5	
Others	2	8	
Days on LVAD	1729.9±626.1	1248.0±638.0	0.005
VWF-LMI (%)	29.7±17.8	55.2±24.4	<0.001
VWF:Ag (%)	94.6±42.2	99.1±51.3	0.921
VWF:RCo (%)	46.4±31.1	57.7±41.9	0.395
VWF:RCo/VWF:Ag	0.47±0.16	0.56±0.23	0.050
LDH (U/L)	416.1±240.5	286.1±149.9	0.011
BUN (mg/dL)	20.4±11.1	17.1±9.5	0.337
Cre (mg/dL)	1.14±0.46	1.01±0.52	0.113

Hb (g/dL)	11.1±2.9	11.8±1.7	0.165
Plt (10 ³ /μL)	177.8±74.8	229.0±93.3	0.049
PT-INR	2.22±0.56	2.38±0.55	0.279
CRP (mg/dL)	0.53±1.34	0.89±1.71	0.120

Data are presented as mean ± standard deviation. Comparison between patients with bleeding events (Bleeding (+)) and patients without bleeding events (Bleeding (-)) was performed using Fisher's exact test, Student's t-test, or the Mann Whitney test. BUN, blood urea nitrogen; Cre, creatinine; CRP, c-reactive protein; DCM, dilated cardiomyopathy; dHCM, dilated hypertrophic cardiomyopathy; Hb, hemoglobin; ICM, ischemic cardiomyopathy; LDH, lactate dehydrogenase; LVAD, left ventricular assist device; Plt, platelet counts; PT-INR, prothrombin time international normalized ratio; VWF-LMI, von Willebrand factor large multimer index; VWF:Ag, von Willebrand factor antigen, VWF:RCo, von Willebrand factor ristocetin cofactor activity; ratio of VWF:RCo to VWF:Ag, VWF:RCo/VWF:Ag.

Figure legend

Figure 1

(A) Distribution of von Willebrand factor (VWF) large multimers. Bands above the 10th lowest were classified as large multimers. Compared with VWF large multimers in control subjects, VWF large multimers of patients with the HeartMate3 were reduced and those of patients with the Jarvik2000 were even further reduced.

(B) The VWF large multimer index (VWF-LMI) differed significantly between patients implanted with the EVAHEART and HeartMate \square ($p<0.001$), EVAHEART and Jarvik2000 ($p<0.001$), HeartMate3 and HeartMate \square ($p<0.001$), and the HeartMate3 and Jarvik2000 ($p<0.001$).

(C) VWF-LMI decreased in a pump speed-dependent manner ($p<0.001$, $r=-0.599$).

Figure 2

(A) The VWF large multimer index (VWF-LMI) positively correlated with the ratio of VWF ristocetin cofactor activity to VWF antigen levels (VWF:RCo/VWF:Ag; $p<0.001$, $r=-0.468$).

(B) Association between device type and VWF:RCo/VWF:Ag. No significant difference was detected between device types.

(C) Pump speed did not correlate with VWF:RCo/VWF:Ag ($p=0.170$, $r=-0.171$).

Figure 3

(A) The VWF large multimer index (VWF-LMI) positively correlated with maximal ristocetin-induced platelet aggregation (RIPA) rate ($p < 0.001$, $r = -0.660$).

(B) Association between device type and maximal RIPA rate. The association of the maximal RIPA rate differed significantly between the EVAHEART and Jarvik 2000 ($p = 0.001$).

(C) Maximal RIPA rates decreased in a pump speed-dependent manner ($p < 0.001$, $r = -0.664$).

Figure 4

Comparison between patients in the 2 groups based on cut-off values determined by receiver operating characteristics curve, using Kaplan-Meier method, log-rank test, and Cox regression analysis revealed (A) a significant increase in bleeding events in the patients with a VWF large multimer index (VWF-LMI) < 42.3 compared to the patients with VWF-LMI ≥ 42.3 ($p < 0.001$, HR 6.96), (B) a significant increase in bleeding events in the patients with a ratio of VWF ristocetin cofactor activity to VWF antigen levels (VWF:RCo/VWF:Ag) < 0.52 compared to patients with VWF:RCo/VWF:Ag ≥ 0.52 ($p = 0.024$, HR 2.89), and (C) a significant increase in bleeding events in patients with maximal ristocetin-induced platelet aggregation (RIPA) rates < 79.2 compared to patients with maximal RIPA rates ≥ 79.2 ($p = 0.001$, HR 13.4). VWF-LMI < 42.3 , VWF:RCo/VWF:Ag < 0.52 , and maximal RIPA rate < 79.2 predicted bleeding events.

Figure 5

(A) Western blotting of each primary antibody. Western blotting was performed on 11 platelet proteins involved in platelet aggregation, including PAR-1, TXA2R, GPIb, GP IIIa, GP VI, FcR γ , P2Y1, P2Y12, 5HTR-2, PGI2R and P-selectin.

(B) Comparison of the levels of platelet proteins, including (a) PAR-1, (b) TXA2R, (c) GPIb, (d) GP IIIa, (e) GP VI, (f) FcR γ , (g) P2Y1, (h) P2Y12, (i) 5HTR-2, (j) PGI2R and (k) P-selectin, between healthy subjects and patients with left ventricular assist devices (LVADs). Of the 11 platelet proteins, only GPIb ($p=0.006$) and GPVI ($p=0.033$) were significantly reduced in patients with LVADs. No significant differences in PAR-1 ($p=0.210$), TXA2R ($p=0.221$), GPIIIa ($p=0.842$), FcR γ ($p=0.678$), P2Y1 ($p=0.072$), P2Y12 ($p=0.188$), 5HTR-2 ($p=0.286$), PGI2R ($p=0.770$), and P-selectin ($p=0.358$) were detected between healthy subjects and patients with LVADs. Levels of platelet proteins were not associated with bleeding events.